Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$37.00
-0.82-2.17%
Last update: Oct 16, 5:04 PM
$37.00
-0.82-2.17%
Genmab AS (GMAB) Stock Price, Quote, News & History
GMABNASDAQ
| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Genmab (NASDAQ:GMAB) through any online brokerage.
Other companies in Genmab’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Genmab has a consensus price target of $40.82.
The stock price for Genmab (NASDAQ: GMAB) is $37 last updated October 16, 2026 at 5:04 PM EDT.
There are no upcoming dividends for Genmab.
Genmab does not have any upcoming earnings scheduled.
There is no upcoming split for Genmab.
Genmab is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
